Lunai Bioworks Inc LNAI
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
Lunai Bioworks (NASDAQ: LNAI) Expands Parkinson's Platform Through Exclusive Tanaist Agreement
-
Lunai Bioworks (Nasdaq: LNAI) Demonstrates AI Chemical-Risk Screening for Generative AI
-
Lunai Bioworks (NASDAQ: LNAI) Issues Correction to Press Release Regarding Second Amended Complaint
-
Lunai Bioworks (Nasdaq: LNAI) Names Six Broker-Dealers in Expanded Naked Short Selling Suit
-
Lunai Bioworks (Nasdaq: LNAI) Signs Definitive Collaboration Agreement with BrainStorm Therapeutics; Initial Parkinson's Disease Data Readout Targeted for First Half of 2027
-
Lunai Bioworks (Nasdaq: LNAI) Names 10 Defendants in Naked Short Selling Fraud Suit
Trading Information
- Previous Close Price
- $1.14
- Day Range
- $1.13–1.20
- 52-Week Range
- $1.13–13.28
- Bid/Ask
- $1.14 / $1.18
- Shares Outstanding
- 4.53M
- Market Cap
- $5.35M
- Volume/Avg
- 11,106 / 180,234
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 151.13
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
Lunai Bioworks Inc is a biopharmaceutical company. Through its subsidiaries, it is mainly focused on developing allogeneic cell and gene therapies to promote stronger immune system responses, potentially for long-term or life-long cancer remission in some of the deadliest cancers. The group is engaged in the development of RENB-DC11 and RENB-DC20 (potential cell therapeutic vaccine candidates for different types of cancer); a proprietary AI platform that analyzes genetics to provide earlier and more accurate cancer diagnosis; and machine learning pipelines that harmonize and analyze complex, heterogeneous datasets to uncover clinically actionable insights. The group's reportable segments are: RENB, BioSymetrics, and RENC. Geographically, it operates in the United States and Netherlands.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 29
- Website
- https://www.renovarogroup.com
Valuation
|
Metric
|
LNAI
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 151.13 |
Price/Cash Flow | — |
Price/Earnings
LNAI
Financial Strength
|
Metric
|
LNAI
|
|---|---|
Quick Ratio | 0.16 |
Current Ratio | 0.19 |
Interest Coverage | −219.81 |
Quick Ratio
LNAI
Profitability
|
Metric
|
LNAI
|
|---|---|
Return on Assets (Normalized) | −35.61% |
Return on Equity (Normalized) | −172.24% |
Return on Invested Capital (Normalized) | −92.12% |
Return on Assets
LNAI
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|?^jr<wV | LOCK|%!bD | $128B | |||
| Moderna Inc
MRNA
| LOCK|!!<bp> | LOCK|$k% | $81B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|xrps<p | LOCK|TjVs | $75B | |||
| argenx SE ADR
ARGX
| LOCK|#&^<%@m | LOCK|J&W | $57B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|mB#K^@< | LOCK|n< | $43B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|c?>$R^ | LOCK|!@@< | $29B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|By@>ZMH | LOCK|>S#B | $25B | |||
| BioNTech SE ADR
BNTX
| LOCK|rr%qx^ | LOCK|C! | $25B | |||
| Incyte Corp
INCY
| LOCK|Qt!lf& | LOCK|r$p | $23B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| LOCK|mwP!y? | LOCK|^< | $15B |
United States